Novaminsulfon Injekt Lichtenstein (Metamizole Sodium Monohydrate)

Metamizole sodium works by non‑selectively inhibiting cyclooxygenase enzymes, which lowers prostaglandin production. This reduction diminishes peripheral sensitisation and influences central pain pathways, resulting in analgesic and antipyretic effects. Additional central mechanisms, such as modulation of opioid receptors, may also contribute, although the complete mechanism is not fully defined.

The appropriate dose of Novaminsulfon Injekt Lichtenstein is determined by the prescribing clinician based on the patient’s condition, severity of pain or fever, and individual health factors. Healthcare professionals follow local guidelines and consider renal, hepatic, and hematologic status when selecting the dosage and route of administration.

Safety data for metamizole sodium in pregnancy and lactation are limited, and the product is generally not recommended without a clear medical justification. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and alternatives with their healthcare provider before using this medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with traditional NSAIDs, metamizole offers strong analgesic and antipyretic effects with a lower incidence of gastrointestinal irritation but carries a risk of rare blood dyscrasias such as agranulocytosis. Unlike opioids, it does not produce typical opioid‑related respiratory depression, making it a useful alternative for patients where opioid use is contraindicated.

Novaminsulfon Injekt Lichtenstein must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If the product must be transported, maintain the cold‑chain conditions throughout the journey to preserve stability.

The medication is supplied as a sterile injectable solution and can be given either intramuscularly or intravenously, depending on clinical need and physician recommendation. Administration should be performed by qualified healthcare personnel using aseptic technique, and the injection site should be monitored for any immediate adverse reactions.

The most serious risks include agranulocytosis, which can lead to severe infections, and rare hypersensitivity reactions such as anaphylaxis, Stevens‑Johnson syndrome, or toxic epidermal necrolysis. Clinicians should monitor complete blood counts regularly, especially during prolonged therapy, and advise patients to seek immediate medical attention if signs of infection or severe skin reactions appear.

Patients with a known hypersensitivity to metamizole, other pyrazolones, or any component of the formulation should avoid this product. It is also contraindicated in individuals with a history of severe blood dyscrasias, such as agranulocytosis, and should be used with caution in patients with significant renal or hepatic impairment.